Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

MK-421

Known as: MK 421, MK421 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1986
Highly Cited
1986
Summary: The novel prodrug-converting-enzyme (CE) inhibitor perindopril (S9490-3) diacid was found to be as potent as ramipril… 
Highly Cited
1985
Highly Cited
1985
The role of converting enzyme (CE) in heart function was studied by assessing the inhibition of CE activity in rat heart tissue… 
Highly Cited
1984
Highly Cited
1984
A number of studies have shown short-term hemodynamic and symptomatic improvement in patients with congestive heart failure… 
  • table I
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
1984
Highly Cited
1984
The mechanism of antihypertensive action of converting enzyme (CE) inhibitors was studied by comparing two compounds of different… 
Highly Cited
1983
Highly Cited
1983
Dietary sodium restriction reduces vascular smooth muscle, particularly renovascular, responsiveness to infused angiotensin II… 
Highly Cited
1982
Highly Cited
1982
Highly Cited
1982
Abstract 1 Two new orally active inhibitors of angiotensin converting enzyme MK421 (enalapril maleate) and its lysine analogue… 
Highly Cited
1982
Highly Cited
1982
1 The disposition of two angiotensin converting-enzyme inhibitor drugs was studied in normal volunteers. One drug was enalapril… 
Highly Cited
1981
Highly Cited
1981
The effects of the new oral converting enzyme inhibitor "MK-421" on blood pressure, plasma renin activity, plasma angiotensin II… 
  • figure 2
  • figure 1
  • figure 4
  • figure 3
Highly Cited
1981
Highly Cited
1981
The parent diacid (N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro of MK-421 inhibited hog plasma angiotensin converting enzyme (ACE…